PMID- 34792864
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220226
IS  - 2578-5745 (Electronic)
IS  - 2578-5745 (Linking)
VI  - 4
IP  - 2
DP  - 2022 Feb
TI  - Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with 
      ANCA-Associated Vasculitis.
PG  - 168-176
LID - 10.1002/acr2.11366 [doi]
AB  - OBJECTIVE: Improved biomarkers of current disease activity and prediction of 
      relapse are needed in antineutrophil cytoplasmic antibody-associated vasculitis 
      (AAV). For clinical relevance, biomarkers must perform well longitudinally in 
      patients on treatment and in patients with nonsevere flares. METHODS: Twenty-two 
      proteins were measured in 347 serum samples from 74 patients with AAV enrolled in 
      a clinical trial. Samples were collected at Month 6 after remission induction, 
      then every 3 months until Month 18, or at the time of flare. Associations of 
      protein concentrations with concurrent disease activity and with future flare 
      were analyzed using mixed-effects models, Cox proportional hazards models, and 
      conditional logistic regression. RESULTS: Forty-two patients had flares during 
      the 12-month follow-up period, and 32 remained in remission. Twenty-two patients 
      had severe flares. Six experimental markers (CXCL13, IL-6, IL-8, IL-15, IL-18BP, 
      and matrix metalloproteinase-3 [MMP-3]) and ESR were associated with disease 
      activity using all three methods (P < 0.05, with P < 0.01 in at least one 
      method). A rise in IL-8, IL-15, or IL-18BP was associated temporally with flare. 
      Combining C-reactive protein (CRP), IL-18BP, neutrophil gelatinase-associated 
      lipocalin (NGAL), and sIL-2Ralpha improved association with active AAV. CXCL13 and 
      MMP-3 were increased during treatment with prednisone, independent of disease 
      activity. Marker concentrations during remission were not predictive of future 
      flare. CONCLUSION: Serum biomarkers of inflammation and tissue damage and repair 
      have been previously shown to be strongly associated with severe active AAV were 
      less strongly associated with active AAV in a longitudinal study that included 
      mild flares and varying treatment. Markers rising contemporaneously with flare or 
      with an improved association in combination merit further study.
CI  - (c) 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on 
      behalf of American College of Rheumatology.
FAU - Monach, Paul A
AU  - Monach PA
AUID- ORCID: 0000-0003-4937-0515
AD  - Boston University, Boston, Massachusetts.
AD  - VA Boston Healthcare System, Brigham and Women's Hospital, Boston, Massachusetts.
FAU - Warner, Roscoe L
AU  - Warner RL
AD  - University of Michigan, Ann Arbor, Michigan.
FAU - Lew, Robert
AU  - Lew R
AD  - Boston University, Boston, Massachusetts.
FAU - Tomasson, Gunnar
AU  - Tomasson G
AD  - University Hospital, Reykjavik, Iceland.
FAU - Specks, Ulrich
AU  - Specks U
AD  - Mayo Clinic, Rochester, Minnesota.
FAU - Stone, John H
AU  - Stone JH
AD  - Massachusetts General Hospital, Boston, Massachusetts.
FAU - Fervenza, Fernando C
AU  - Fervenza FC
AD  - Mayo Clinic, Rochester, Minnesota.
FAU - Hoffman, Gary S
AU  - Hoffman GS
AD  - Cleveland Clinic, Cleveland, Ohio.
FAU - Kallenberg, Cees G M
AU  - Kallenberg CGM
AD  - University Medical Center, Groningen, The Netherlands.
FAU - Langford, Carol A
AU  - Langford CA
AD  - University Medical Center, Groningen, The Netherlands.
FAU - Seo, Philip
AU  - Seo P
AD  - Johns Hopkins University, Baltimore, Maryland.
FAU - St Clair, E William
AU  - St Clair EW
AD  - Duke University, Durham, North Carolina.
FAU - Spiera, Robert
AU  - Spiera R
AD  - Hospital for Special Surgery, New York, New York.
FAU - Johnson, Kent J
AU  - Johnson KJ
AD  - University of Michigan, Ann Arbor, Michigan.
FAU - Merkel, Peter A
AU  - Merkel PA
AD  - University of Pennsylvania, Philadelphia.
LA  - eng
GR  - N01AI15416/AI/NIAID NIH HHS/United States
GR  - RC1 AR058303/AR/NIAMS NIH HHS/United States
GR  - U54 RR019497/RR/NCRR NIH HHS/United States
GR  - P60 AR047785/AR/NIAMS NIH HHS/United States
GR  - U54 AR057319/AR/NIAMS NIH HHS/United States
GR  - N01 AI15416/Immune Tolerance Network/
PT  - Journal Article
DEP - 20211118
PL  - United States
TA  - ACR Open Rheumatol
JT  - ACR open rheumatology
JID - 101740025
PMC - PMC8843765
EDAT- 2021/11/19 06:00
MHDA- 2021/11/19 06:01
PMCR- 2021/11/18
CRDT- 2021/11/18 12:38
PHST- 2021/09/01 00:00 [revised]
PHST- 2021/06/03 00:00 [received]
PHST- 2021/09/13 00:00 [accepted]
PHST- 2021/11/19 06:00 [pubmed]
PHST- 2021/11/19 06:01 [medline]
PHST- 2021/11/18 12:38 [entrez]
PHST- 2021/11/18 00:00 [pmc-release]
AID - ACR211366 [pii]
AID - 10.1002/acr2.11366 [doi]
PST - ppublish
SO  - ACR Open Rheumatol. 2022 Feb;4(2):168-176. doi: 10.1002/acr2.11366. Epub 2021 Nov 
      18.